Definition · Plain-language
Risk Management Plan (RMP)
A Risk Management Plan (RMP) is a document, required in the EU, that describes what is known and not known about a medicine’s safety and sets out how its risks will be characterised, minimised and monitored.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What an RMP is
A Risk Management Plan is a detailed description of a medicine’s safety profile together with a plan for managing its risks across its life cycle. In the EU, applicants must submit an RMP when seeking marketing authorisation, and it is updated thereafter. The plan brings together what is known about the product’s risks, what remains uncertain, and the concrete measures — both monitoring activities and interventions — chosen to keep the medicine’s benefit-risk balance favourable in real-world use, complementing the broader pharmacovigilance system.
What it contains
An RMP typically includes a safety specification summarising the important identified risks, important potential risks and missing information for the medicine; a pharmacovigilance plan setting out routine and any additional activities to characterise and monitor those risks, such as post-authorisation safety studies; and a description of risk-minimisation measures. These measures may be routine, such as the product information and labelling, or additional, such as educational materials for prescribers or controlled-access programmes. The plan explains how the effectiveness of these measures will be evaluated.
How it fits pharmacovigilance
The RMP is a product-specific instrument that operationalises risk management for an individual medicine, whereas the Pharmacovigilance System Master File describes the holder’s overall system. As safety knowledge evolves — through signal detection, studies and accumulating reports — the RMP is revised to reflect new risks, retire resolved concerns or adjust risk-minimisation activities. In this way the RMP serves as a living bridge between safety surveillance and concrete actions intended to protect patients, under regulatory oversight.
Key facts
At a glance
- Definition: Document describing a medicine’s safety profile and risk-management plan.
- Stands for: Risk Management Plan (RMP).
- Requirement: EU requirement at marketing authorisation, updated thereafter.
- Core parts: Safety specification, pharmacovigilance plan, risk-minimisation measures.
- Scope: Product-specific (a single medicine).
- Nature: A living document, revised as safety knowledge changes.
Common misconceptions
What people often get wrong
Often heard: A Risk Management Plan and a Pharmacovigilance System Master File are the same thing.
Actually: An RMP is product-specific and addresses one medicine’s risks. A PSMF describes the holder’s overall pharmacovigilance system. They are distinct documents.
Often heard: An RMP is finalised at approval and not changed again.
Actually: The RMP is a living document, updated as new safety information emerges or as risk-minimisation measures are added, modified or retired.
Often heard: An RMP only lists confirmed risks of the medicine.
Actually: It addresses important identified risks, important potential risks and missing information — including uncertainties, not just established risks.
Going deeper
